Company intelligence / Profile preview

Macleods Pharmaceuticals Limited

Mumbai, Maharashtra, Indiamacleodspharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Macleods Pharmaceuticals Limited operates at commercial scale with an extensive global presence. It supplies more than one hundred generic drugs worldwide—including the US—and has recently launched pretomanid for drug-resistant tuberculosis under license from TB Alliance. The company’s R&D pipeline includes fixed-dose combinations for diabetes currently in Phase II trials.

Therapeutic areas: Infectious DiseasesPulmonologyEndocrinologyRheumatologyCardiovascularWomen's Health
Modalities: Small molecules (APIs and finished dosages)Fixed-dose combinationsNew drug delivery systems
Industry: Biotech

Drug pipeline

2 assets

Macprot

Unknown

1 more asset in the full pipeline.

Partnerships

TB Alliance – licensing agreement to supply pretomanid for DR-TB to low/middle-income countries

Beyond the preview

Go deeper on Macleods Pharmaceuticals Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macleods Pharmaceuticals Limited.